OBJECTIVE: To probe into the new model of delicacy management of key monitoring drugs based on diagnosis related groups（ DRG） data

so as to pave the way for continuous improvement of the expense management model.METHODS: To compare the application of key monitoring drugs on hospitalized patients before（ from Sept. to Nov.2018） and after（ from Sept.to Nov.2019） the implementation of key monitoring drugs control the First Hospital of Wuhan（ hereinafter referred to as"our hospital"）

to select the top DRG group for statistical analysis of the number of cases

average cost per time and drug cost

and to compare the expense difference before and after control.RESULTS:After the control of key monitoring drugs

the proportion of expense of key monitoring drugs accounted for total drugs in clinical departments was significantly decreased

especially in the departments of neurology and nephrology. Among them

the drug expenses in BR23 group（ cerebral ischemic disease

accompanied with comorbidities and concomitant diseases） and BX23 group（ peripheral nerve disease

accompanied with comorbidities and concomitant diseases） were greatly decreased compared with that of before the control of key monitoring drugs

with statistically significant difference（ P < 0. 001）; and the drug expense in LR11 group（ renal failure

accompanied with comorbidities and concomitant diseases） was significantly decreased

with statistically significant difference（ P < 0. 05）. CONCLUSIONS:The implementation of delicacy management of key monitoring drugs based on DRG has standardized the rational application of key monitoring drugs in our hospital in a certain degree

which has provided a reference for continuous optimization of the expense management model.